Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials
Table 1
Listing of location and details of current clinical trials being completed to investigate the potential role of bone marrow-derived progenitor cell therapeutics for the treatment of ischemic stroke.
Location of Study
Study Design
Deliver Route
Sample Size
Cell Type
Inclusion Criteria
Outcomes
Time Window
United States (The University of Texas in Houston)
Single arm
IV
10
Autologous BMMCs
- MCA stroke - 18–80 yo - NIHSS 6 to 20
Safety and feasibility
24 to 72 hrs
Taiwan (The China Medical University Hospital)
Randomized (cell infusion versus conventional treatment)
IC
30
Autologous peripheral blood CD34+ cells
- Stable deficits hemiplegia - 35–70 yo - NIHSS 9 to 20
Safety and efficacy
6 months to 5 years
Spain (Hospital Universitario Central de Asturias)
Single arm
IA
20
Autologous CD34+ bone marrow cells
- MCA stroke - 18–80 yo - NIHSS ≥ 8
Safety
5 to 9 days
France (University Hospital of Grenoble)
Randomized (Control versus 2 treatment groups)
IV
30
Autologous bone marrow derived progenitor cells
- Carotid territory stroke - 18–65 yo - NIHSS 2
Feasibility and tolerability
6 weeks
United Kingdom (Imperial College London)
Single arm
IA
10
Autologous CD34+ bone marrow cells
- MCA stroke - 30–80 yo - Severe stroke conforming to the TACS phenotype (weakness, homonymous hemianopia and a focal cognitive deficit
Safety and tolerability
7 days
Brazil (Federal University of Rio de Janeiro)
2 arms (non randomized: 10 IA/5IV)
IV/IA
15
Autologous BMMCs
- MCA stroke - 18–75 yo - NIHSS 4 to 20
Safety
3 hrs to 90 days
IV: intravenous; IA: intra-arterial; IC: intracerebral; BMMC: bone marrow mononuclear cells; MCA: middle cerebral artery; NIHSS: National Institutes of Health Stroke Scale; TACS: total anterior circulation stroke.
